BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
28 results:

  • 1. Relevance of mutations in protein deubiquitinases genes and
    Pękul M; Szczepaniak M; Kober P; Rusetska N; Mossakowska BJ; Baluszek S; Kowalik A; Maksymowicz M; Zieliński G; Kunicki J; Witek P; Bujko M
    Front Endocrinol (Lausanne); 2024; 15():1302667. PubMed ID: 38487343
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Molecular Features of Resected Melanoma brain Metastases, clinical outcomes, and Responses to Immunotherapy.
    Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
    JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Can a signature molecular-profile define disparate survival in braf-positive Gliosarcoma and identify novel targets for therapeutic intervention?
    Gandhi P; Khare R; Garg N; Mishra J
    J Cancer Res Ther; 2022; 18(1):224-230. PubMed ID: 35381788
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Real-world data on melanoma brain metastases and survival outcome.
    Pedersen S; Møller S; Donia M; Persson GF; Svane IM; Ellebaek E
    Melanoma Res; 2022 Jun; 32(3):173-182. PubMed ID: 35256571
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.
    Pratt D; Abdullaev Z; Papanicolau-Sengos A; Ketchum C; Panneer Selvam P; Chung HJ; Lee I; Raffeld M; Gilbert MR; Armstrong TS; Pytel P; Borys E; Klonoski JM; McCord M; Horbinski C; Brat D; Perry A; Solomon D; Eberhart C; Giannini C; Quezado M; Aldape K
    Acta Neuropathol; 2022 Mar; 143(3):403-414. PubMed ID: 35103816
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genetic and epigenetic characterization of posterior pituitary tumors.
    Schmid S; Solomon DA; Perez E; Thieme A; Kleinschmidt-DeMasters BK; Giannini C; Reinhardt A; Asa SL; Mete O; Stichel D; Siewert C; Dittmayer C; Hasselblatt M; Paulus W; Nagel C; Harter PN; Schittenhelm J; Honegger J; Rushing E; Coras R; Pfister SM; Buslei R; Koch A; Perry A; Jones DTW; von Deimling A; Capper D; Lopes MB
    Acta Neuropathol; 2021 Dec; 142(6):1025-1043. PubMed ID: 34661724
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer.
    Nguyen HG; Lundström O; Blank A; Dawson H; Lugli A; Anisimova M; Zlobec I
    Mod Pathol; 2022 Feb; 35(2):240-248. PubMed ID: 34475526
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Skull Base Tumors: Neuropathology and clinical Implications.
    Bi WL; Santagata S
    Neurosurgery; 2022 Mar; 90(3):243-261. PubMed ID: 34164689
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
    Syeda MM; Wiggins JM; Corless BC; Long GV; Flaherty KT; Schadendorf D; Nathan PD; Robert C; Ribas A; Davies MA; Grob JJ; Gasal E; Squires M; Marker M; Garrett J; Brase JC; Polsky D
    Lancet Oncol; 2021 Mar; 22(3):370-380. PubMed ID: 33587894
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Recent advances in molecular targeted therapy for unresectable and metastatic braf-mutated melanoma.
    Kiniwa Y; Okuyama R
    Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Cures with b-raf inhibitors as single agents in metastatic b-raf mutated melanoma: Curb your enthusiasm?
    Dasanu CA
    J Oncol Pharm Pract; 2021 Jan; 27(1):205-206. PubMed ID: 33241730
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Exploring DNA Methylation for Prognosis and Analyzing the Tumor Microenvironment in Pleomorphic Xanthoastrocytoma.
    Tang K; Kurland D; Vasudevaraja V; Serrano J; Delorenzo M; Radmanesh A; Thomas C; Spino M; Gardner S; Allen JC; Nicolaides T; Osorio DS; Finlay JL; Boué DR; Snuderl M
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):880-890. PubMed ID: 32594172
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Virtual biopsy using MRI radiomics for prediction of braf status in melanoma brain metastasis.
    Shofty B; Artzi M; Shtrozberg S; Fanizzi C; DiMeco F; Haim O; Peleg Hason S; Ram Z; Bashat DB; Grossman R
    Sci Rep; 2020 Apr; 10(1):6623. PubMed ID: 32313236
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pineal Gland Tumor Microenvironment.
    Choque-Velasquez J; Baluszek S; Colasanti R; Muhammad S; Hernesniemi J
    Adv Exp Med Biol; 2020; 1296():137-150. PubMed ID: 34185290
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Primary Solitary Intracranial Malignant Melanoma: A Systematic Review of Literature.
    Arai N; Kagami H; Mine Y; Ishii T; Inaba M
    World Neurosurg; 2018 Sep; 117():386-393. PubMed ID: 29959081
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.
    Deng MY; Sill M; Chiang J; Schittenhelm J; Ebinger M; Schuhmann MU; Monoranu CM; Milde T; Wittmann A; Hartmann C; Sommer C; Paulus W; Gärtner J; Brück W; Rüdiger T; Leipold A; Jaunmuktane Z; Brandner S; Giangaspero F; Nozza P; Mora J; Morales la Madrid A; Cruz Martinez O; Hansford JR; Pietsch T; Tietze A; Hernáiz-Driever P; Stoler I; Capper D; Korshunov A; Ellison DW; von Deimling A; Pfister SM; Sahm F; Jones DTW
    Acta Neuropathol; 2018 Aug; 136(2):239-253. PubMed ID: 29766299
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
    Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
    Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Genomic Alterations in Sporadic Pituitary Tumors.
    Bi WL; Larsen AG; Dunn IF
    Curr Neurol Neurosci Rep; 2018 Feb; 18(1):4. PubMed ID: 29396598
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Dabrafenib and trametinib in brafV600E mutated glioma.
    Brown NF; Carter T; Kitchen N; Mulholland P
    CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. outcome Evaluation of Patients with Limited brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy.
    Pessina F; Navarria P; Tomatis S; Cozzi L; Franzese C; Di Guardo L; Ascolese AM; Reggiori G; Franceschini D; Del Vecchio M; Bello L; Scorsetti M
    World Neurosurg; 2017 Sep; 105():184-190. PubMed ID: 28578123
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.